Impact of Octreotide Long-Acting Release on Tumour Growth Control as a First-Line Treatment in Neuroendocrine Tumours of Pancreatic Origin

2013 ◽  
Vol 98 (2) ◽  
pp. 137-143 ◽  
Author(s):  
H. Jann ◽  
T. Denecke ◽  
M. Koch ◽  
U.F. Pape ◽  
B. Wiedenmann ◽  
...  
Keyword(s):  
Tumour Growth ◽  
Neuroendocrine Tumours ◽  
Growth Control ◽  
Line Treatment ◽  
First Line ◽  
Long Acting ◽  
Pancreatic Origin ◽  
First Line Treatment

scholarly journals Comparative effectiveness of long-acting antipsychotics: issues and challenges from a pragmatic randomised study

2015 ◽  
Vol 25 (1) ◽  
pp. 21-23 ◽  
Author(s):  
G. Ostuzzi ◽  
C. Barbui
Keyword(s):  
Clinical Practice ◽  
Comparative Effectiveness ◽  
Psychotic Disorders ◽  
Paliperidone Palmitate ◽  
Line Treatment ◽  
First Line ◽  
Haloperidol Decanoate ◽  
Randomised Study ◽  
Long Acting ◽  
First Line Treatment

Although long-acting antipsychotics are widely used in individuals with psychotic disorders, it is unclear which long-acting preparation should be considered as first-line treatment in clinical practice. In this commentary, the main strengths and weaknesses of a recently published pragmatic randomised study comparing long-acting paliperidone palmitate v. long-acting haloperidol decanoate are briefly analysed.

Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours

2017 ◽  
Vol 49 (5) ◽  
pp. 568-571
Author(s):  
Côme Lepage ◽  
Laetitia Dahan ◽  
Nadia Bouarioua ◽  
Christos Toumpanakis ◽  
Jean-Louis Legoux ◽  
...  
Keyword(s):  
Maintenance Therapy ◽  
Neuroendocrine Tumours ◽  
Line Treatment ◽  
First Line ◽  
Pancreatic Neuroendocrine Tumours ◽  
First Line Treatment

Long-acting injectable antipsychotics: shall the last be first?

CNS Spectrums ◽  
2014 ◽  
Vol 19 (1) ◽  
pp. 3-5 ◽  
Author(s):  
Stephen M. Stahl
Keyword(s):  
Paradigm Shift ◽  
Line Treatment ◽  
First Line ◽  
Long Acting ◽  
First Line Treatment

ISSUE:A paradigm shift is afoot in which the “last shall be first,” namely, use of long-acting injectable (LAI) antipsychotics, rather than being reserved for use only at the last stages of schizophrenia, may be shifting to first-line treatment of early episodes of this illness.

Sign in / Sign up

Export Citation Format

Share Document